Human immunodeficiency virus (HIV) infects human arterial smooth muscle cells in vivo and in vitro: Implications for the pathogenesis of HIV-mediated vascular disease

American Journal of Pathology

Volumn 172, Issue 4, 2008, Pages 1100-1111

  Eugenin, Eliseo A ^a   Morgello, Susan ^b   Klotman, Mary E ^b   Mosoian, Arevik ^b   Lento, Patrick A ^b   Berman, Joan W ^a   Schecter, Alison D ^b  

^a ALBERT EINSTEIN COLLEGE OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR; ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; CD4 ANTIGEN; CHEMOKINE RECEPTOR CCR5; CHEMOKINE RECEPTOR CXCR4; DIDANOSINE; EFAVIRENZ; LAMIVUDINE; LOPINAVIR PLUS RITONAVIR; NEVIRAPINE; TENOFOVIR; TENOFOVIR DISOPROXIL;

ADULT; AGED; ARTERY MUSCLE; ARTICLE; ATHEROSCLEROSIS; CELL INFILTRATION; CELL PROLIFERATION; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE EXACERBATION; DYSLIPIDEMIA; ENDOCYTOSIS; FEMALE; HIGHLY ACTIVE ANTIRETROVIRAL THERAPY; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUMAN TISSUE; IN VITRO STUDY; IN VIVO STUDY; LIFE EXPECTANCY; MACROPHAGE ACTIVATION; MALE; MONOCYTE; PRIORITY JOURNAL; RISK FACTOR; SMOOTH MUSCLE FIBER; VASCULAR DISEASE; VIRUS PATHOGENESIS;

EID: 42049101411     PISSN: 00029440     EISSN: None     Source Type: Journal    
DOI: 10.2353/ajpath.2008.070457     Document Type: Article

References (65)

1. Bokazhanova A, Rutherford GW: The epidemiology of HIV and AIDS in the world. Coll Antropol 2006, 30(Suppl 2):3-10
2. de Saint Martin L, Vandhuick O, Guillo P, Bellein V, Bressollette L, Roudaut N, Amaral A, Pasquier E: Premature atherosclerosis in HIV positive patients and cumulated time of exposure to antiretroviral therapy (SHIVA study). Atherosclerosis 2006, 185:361-367
3. Hsue PY, Giri K, Erickson S, MacGregor JS, Younes N, Shergill A, Waters DD: Clinical features of acute coronary syndromes in patients with human immunodeficiency virus infection. Circulation 2004, 109:316-319
4. Segev A, Cantor WJ, Strauss BH: Outcome of percutaneous coronary intervention in HIV-infected patients. Catheter Cardiovasc Interv 2006, 68:879-881
5. van Wijk JP, de Koning EJ, Cabezas MC, Joven J, op't Roodt J, Rabelink TJ, Hoepelman AM: Functional and structural markers of atherosclerosis in human immunodeficiency virus-infected patients. J Am Coll Cardiol 2006, 47:1117-1123
6. Barbaro G, Barbarini G, Pellicelli AM: HIV-associated coronary arteritis in a patient with fatal myocardial infarction. N Engl J Med 2001, 344:1799-1800
7. Fisher SD, Miller TL, Lipshultz SE: Impact of HIV and highly active antiretroviral therapy on leukocyte adhesion molecules, arterial inflammation, dyslipidemia, and atherosclerosis. Atherosclerosis 2006, 185:1-11
8. Galli M, Ridolfo AL, Gervasoni C: Cardiovascular disease risk factors in HIV-infected patients in the HAART era. Ann NY Acad Sci 2001, 946:200-213
9. Grody WW, Cheng L, Lewis W: Infection of the heart by the human immunodeficiency virus. Am J Cardiol 1990, 66:203-206
10. Kan H, Xie Z, Finkel MS: HIV gp120 enhances NO production by cardiac myocytes through p38 MAP kinase-mediated NF-kappaB activation. Am J Physiol Heart Circ Physiol 2000, 279:H3138-H3143
11. Twu C, Liu NQ, Popik W, Bukrinsky M, Sayre J, Roberts J, Rania S, Bramhandam V, Roos KP, MacLellan WR, Fiala M: Cardiomyocytes undergo apoptosis in human immunodeficiency virus cardiomyopathy through mitochondrion- and death receptor-controlled pathways, Proc Natl Acad Sci USA 2002, 99:14386-14391
12. Shor-Posner G, Basit A, Lu Y, Cabrejos C, Chang J, Fletcher M, Mantero-Atienza E: Hypocholesterolemia is associated with immune dysfunction in early human immunodeficiency infection, Am J Med 1993, 94:515-519
13. Grinspoon SK: Metabolic syndrome and cardiovascular disease in patients with human immunodeficiency virus. Am J Med 2005, 118(Suppl 2):23S-28S
14. Cotter BR: Endothelial dysfunction in HIV infection. Curr HIV/AIDS Rep 2006, 3:126-131
15. Schecter AD, Berman AB, Taubman MB: Chemokine receptors in vascular smooth muscle. Microcirculation 2003, 10:265-272
16. Schecter AD, Berman AB, Yi L, Mosoian A, McManus CM, Berman JW, Klotman ME, Taubman MB: HIV envelope gp120 activates human arterial smooth muscle cells. Proc Natl Acad Sci USA 2001, 98:10142-10147
17. Schecter AD, Calderon TM, Berman AB, McManus CM, Fallon JT, Rossikhina M, Zhao W, Christ G, Berman JW, Taubman MB: Human vascular smooth muscle cells possess functional CCR5. J Biol Chem 2000, 275:5466-5471
18. Moore JP, Trkola A, Dragic T: Co-receptors for HIV-1 entry. Curr Opin Immunol 1997, 9:551-562
19. Virmani R, Kolodgie FD, Burke AP, Farb A, Schwartz SM: Lessons from sudden coronary death: a comprehensive morphological classification scheme for atherosclerotic lesions. Arterioscler Thromb Vasc Biol 2000, 20:1262-1275
20. Schecter AD, Giesen PL, Taby O, Rosenfield CL, Rossikhina M, Fyfe BS, Kohtz DS, Fallon JT, Nemerson Y, Taubman MB: Tissue factor expression in human arterial smooth muscle cells. TF is present in three cellular pools after growth factor stimulation. J Clin Invest 1997, 100:2276-2285
21. Schecter AD, Rollins BJ, Zhang YJ, Charo IF, Fallon JT, Rossikhina M, Giesen PL, Nemerson Y, Taubman MB: Tissue factor is induced by monocyte chemoattractant protein-1 in human aortic smooth muscle and THP-1 cells. J Biol Chem 1997, 272:28568-28573
22. Eugenin EA, Osiecki K, Lopez L, Goldstein H, Calderon TM, Berman JW: CCL2/monocyte chemoattractant protein-1 mediates enhanced transmigration of human immunodeficiency virus (HIV)-infected leukocytes across the blood-brain barrier: a potential mechanism of HIV-CNS invasion and NeuroAIDS. J Neurosci 2006, 26:1098-1106
23. Eugenin EA, Berman JW: Chemokine-dependent mechanisms of leukocyte trafficking across a model of the blood-brain barrier. Methods 2003, 29:351-361
24. Eugenin EA, Gamss R, Buckner C, Buono D, Klein RS, Schoenbaum EE, Calderon TM, Berman JW: Shedding of PECAM-1 during HIV infection: a potential role for soluble PECAM-1 in the pathogenesis of NeuroAIDS. J Leukoc Biol 2006, 79:444-452
25. Pierson TC, Doms RW: HIV-1 entry and its inhibition. Curr Top Microbiol Immunol 2003, 281:1-27
26. Pohlmann S, Doms RW: Evaluation of current approaches to inhibit HIV entry. Curr Drug Targets Infect Disord 2002, 2:9-16
27. Sieczkarski SB, Whittaker GR: Viral entry. Curr Top Microbiol Immunol 2005, 285:1-23
28. Diaz-Griffero F, Hoschander SA, Brojatsch J: Endocytosis is a critical step in entry of subgroup B avian leukosis viruses. J Virol 2002, 76:12866-12876
29. Gu L, Okada Y, Clinton SK, Gerard C, Sukhova GK, Libby P, Rollins BJ: Absence of monocyte chemoattractant protein-1 reduces atherosclerosis in low density lipoprotein receptor-deficient mice. Mol Cell 1998, 2:275-281
30. Hoffman RM, Currier JS: Management of antiretroviral treatmentrelated complications. Infect Dis Clin North Am 2007, 21:103-132
31. Holtgrave DR: Causes of the decline in AIDS deaths, United States, 1995-2002: prevention, treatment or both? Int J STD AIDS 2005, 16:777-781
32. Highleyman L: Mortality trends: toward a new definition of AIDS? BETA 2005, 17:18-28
33. Sackoff JE, Hanna DB, Pfeiffer MR, Torian LV: Causes of death among persons with AIDS in the era of highly active antiretroviral therapy: New York City. Ann Intern Med 2006, 145:397-406
34. Stewart S, Wilkinson D, Becker A, Askew D, Ntyintyane L, McMurray JJ, Sliwa K: Mapping the emergence of heart disease in a black, urban population in Africa: the Heart of Soweto Study. Int J Cardiol 2006, 108:101-108
35. Sudano I, Spieker LE, Noll G, Corti R, Weber R, Luscher TF: Cardiovascular disease in HIV infection. Am Heart J 2006, 151:1147-1155
36. Obel N, Thomsen HF, Kronborg G, Larsen CS, Hildebrandt PR, Sorensen HT, Gerstoft J: Ischemic heart disease in HIV-infected and HIV-uninfected individuals: a population-based cohort study. Clin Infect Dis 2007, 44:1625-1631
37. Paton P, Tabib A, Loire R, Tete R: Coronary artery lesions and human immunodeficiency virus infection. Res Virol 1993, 144:225-231
38. Periard D, Telenti A, Sudre P, Cheseaux JJ, Halfon P, Reymond MJ, Marcovina SM, Glauser MP, Nicod P, Darioli R, Mooser V: Atherogenic dyslipidemia in HIV-infected individuals treated with protease inhibitors: the Swiss HIV Cohort Study. Circulation 1999, 100:700-705
39. Tabib A, Leroux C, Mornex JF, Loire R: Accelerated coronary atherosclerosis and arteriosclerosis in young human-immunodeficiency-virus- positive patients. Coron Artery Dis 2000, 11:41-46
40. Bobryshev YV: Identification of HIV-1 in the aortic wall of AIDS patients. Atherosclerosis 2000, 152:529-530
41. Mujawar Z, Rose H, Morrow MP, Pushkarsky T, Dubrovsky L, Mukhamedova N, Fu Y, Dart A, Orenstein JM, Bobryshev YV, Bukrinsky M, Sviridov D: Human immunodeficiency virus impairs reverse cholesterol transport from macrophages. PLoS Biol 2006, 4:e365
42. Tinkle BT, Ngo L, Luciw PA, Maciag T, Jay G: Human immunodeficiency virus-associated vasculopathy in transgenic mice. J Virol 1997, 71:4809-4814
43. Tinkle BT, Ueda H, Ngo L, Luciw PA, Shaw K, Rosen CA, Jay G: Transgenic dissection of HIV genes involved in lymphoid depletion. J Clin Invest 1997, 100:32-39
44. Baliga RS, Chaves AA, Jing L, Ayers LW, Bauer JA: AIDS-related vasculopathy: evidence for oxidative and inflammatory pathways in murine and human AIDS. Am J Physiol Heart Circ Physiol 2005, 289:H1373-H1380
45. Rahmani M, Cruz RP, Granville DJ, McManus BM: Allograft vasculopathy versus atherosclerosis. Circ Res 2006, 99:801-815
46. Hansson GK: Immune mechanisms in atherosclerosis. Arterioscler Thromb Vasc Biol 2001, 21:1876-1890
47. Libby P, Geng YJ, Aikawa M, Schoenbeck U, Mach F, Clinton SK, Sukhova GK, Lee RT: Macrophages and atherosclerotic plaque stability. Curr Opin Lipidol 1996, 7:330-335
48. Bobardt MD, Salmon P, Wang L, Esko JD, Gabuzda D, Fiala M, Trono D, Van der Schueren B, David G, Gallay PA: Contribution of proteoglycans to human immunodeficiency virus type 1 brain invasion. J Virol 2004, 78:6567-6584
49. Gallay P: Syndecans and HIV-1 pathogenesis. Microbes Infect 2004, 6:617-622
50. Weiss JM, Nath A, Major EO, Berman JW: HIV-1 Tat induces monocyte chemoattractant protein-1-mediated monocyte transmigration across a model of the human blood-brain barrier and up-regulates CCR5 expression on human monocytes. J Immunol 1999, 163:2953-2959
51. Kielian M, Jungerwirth S: Mechanisms of enveloped virus entry into cells. Mol Biol Med 1990, 7:17-31
52. Marechal V, Prevost MC, Petit C, Perret E, Heard JM, Schwartz O: Human immunodeficiency virus type 1 entry into macrophages mediated by macropinocytosis. J Virol 2001, 75:11166-11177
53. Pelchen-Matthews A, Kramer B, Marsh M: Infectious HIV-1 assembles in late endosomes in primary macrophages. J Cell Biol 2003, 162:443-455
54. Wiley RD, Gummuluru S: Immature dendritic cell-derived exosomes can mediate HIV-1 trans infection. Proc Natl Acad Sci USA 2006, 103:738-743
55. Venkatesan S, Rose JJ, Lodge R, Murphy PM, Foley JF: Distinct mechanisms of agonist-induced endocytosis for human chemokine receptors CCR5 and CXCR4. Mol Biol Cell 2003, 14:3305-3324
56. Granelli-Piperno A, Shimeliovich I, Pack M, Trumpfheller C, Steinman RM: HIV-1 selectively infects a subset of nonmaturing BDCA1-positive dendritic cells in human blood. J Immunol 2006, 176:991-998
57. Brack-Werner R: Astrocytes: hIV cellular reservoirs and important participants in neuropathogenesis. AIDS 1999, 13:1-22
58. Eugenin EA, Berman JW: Gap junctions mediate human immunodeficiency virus-bystander killing in astrocytes. J Neurosci 2007, 27:12844-12850
59. Burleigh L, Lozach PY, Schiffer C, Staropoli I, Pezo V, Porrot F, Canque B, Virelizier JL, Arenzana-Seisdedos F, Amara A: Infection of dendritic cells (DCs), not DC-SIGN-mediated internalization of human immunodeficiency virus, is required for long-term transfer of virus to T cells. J Virol 2006, 80:2949-2957
60. Geijtenbeek TB, Kwon DS, Torensma R, van Vliet SJ, van Duijnhoven GC, Middel J, Cornelissen IL, Nottet HS, KewalRamani VN, Littman DR, Figdor CG, van Kooyk Y: DC-SIGN, a dendritic cell-specific HIV-1-binding protein that enhances trans-infection of T cells. Cell 2000, 100:587-597
61. Koch AE, Kunkel SL, Harlow LA, Johnson B, Evanoff HL, Haines GK, Burdick MD, Pope RM, Strieter RM: Enhanced production of monocyte chemoattractant protein-1 in rheumatoid arthritis. J Clin Invest 1992, 90:772-779
62. Villiger PM, Terkeltaub R, Lotz M: Monocyte chemoattractant protein-1 (MCP-1) expression in human articular cartilage. Induction by peptide regulatory factors and differential effects of dexamethasone and retinoic acid, J Clin Invest 1992, 90:488-496
63. Villiger PM, Terkeltaub R, Lotz M: Production of monocyte chemoattractant protein-1 by inflamed synovial tissue and cultured synoviocytes. J Immunol 1992, 149:722-727
64. Yla-Herttuala S, Lipton BA, Rosenfeld ME, Sarkioja T, Yoshimura T, Leonard EJ, Witztum JL, Steinberg D: Expression of monocyte chemoattractant protein 1 in macrophage-rich areas of human and rabbit atherosclerotic lesions. Proc Natl Acad Sci USA 1991, 88:5252-5256
65. Schepers A, Eefting D, Bonta PI, Grimbergen JM, de Vries MR, van Weel V, de Vries CJ, Egashira K, van Bockel JH, Quax PH: Anti-MCP-1 gene therapy inhibits vascular smooth muscle cells proliferation and attenuates vein graft thickening both in vitro and in vivo. Arterioscler Thromb Vasc Biol 2006, 26:2063-2069